Brain tumors are a near-certain death sentence, and the treatment process is notoriously arduous and unrelenting. Yet there is evidence to suggest that there may be a way for us to alleviate some of the pain and other treatment-related symptoms for patients. Dr. Thomas Seyfried, professor of biology at Boston College and associate editor of the journal Nutrition and Metabolism, joins host Dr. Bruce Bloom to explore the possibility of combining chemotherapy with a calorie-restricted ketogenic diet, as a means to extend and improve the lives of brain cancer patients.
Adding a Ketogenic Diet to Chemo: Improved Outcomes?

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Brain tumors are a near-certain death sentence, and the treatment process is notoriously arduous and unrelenting. Yet there is evidence to suggest that there may be a way for us to alleviate some of the pain and other treatment-related symptoms for patients. Dr. Thomas Seyfried, professor of biology at Boston College and associate editor of the journal Nutrition and Metabolism, joins host Dr. Bruce Bloom to explore the possibility of combining chemotherapy with a calorie-restricted ketogenic diet, as a means to extend and improve the lives of brain cancer patients.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Partnering with Patients: Building Effective Communication and Support in HF Care
A Practical Guide to Prescribing in HF
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?